Hostname: page-component-745bb68f8f-b6zl4 Total loading time: 0 Render date: 2025-02-05T17:07:08.220Z Has data issue: false hasContentIssue false
  • English
  • Français

The roles of miR-101, miR-1183 and miR-1299 in acute rheumatic fever and rheumatic heart disease

Published online by Cambridge University Press:  03 February 2025

Ece Korkmaz Open the ORCID record for Ece Korkmaz [Opens in a new window] ,
Dolunay Gürses Open the ORCID record for Dolunay Gürses [Opens in a new window] ,
Gökhan Çetin  and
Hande Senol
Ece Korkmaz
Affiliation:
Department of Pediatrics, Pamukkale University, Denizli, Turkey
Dolunay Gürses*
Affiliation:
Department of Pediatric Cardiology, Pamukkale University Faculty of Medicine, Denizli, Turkey
Gökhan Çetin
Affiliation:
Department of Medical Genetics, Pamukkale University, Denizli, Turkey
Hande Senol
Affiliation:
Department of Biostatistics, Pamukkale University, Denizli, Turkey
*
Corresponding author: Dolunay Gürses; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Acute rheumatic fever commonly causes carditis in children. It is critical to have biomarkers for diagnostic and prognostic purposes. We aimed to investigate the expressions of miR-101, miR-1183, and miR-1299 in children with acute rheumatic fever and rheumatic heart disease and determine their potential as diagnostic biomarkers.

Methods:

This cross-sectional study was conducted on 69 paediatric acute rheumatic fever patients and 27 gender and age-matched controls. The clinical findings were noted from medical records, echocardiography was repeated, and plasma miR-101, miR-1183, and miR-1299 expressions were studied using RT-PCR.

Results:

Out of 54 patients with carditis, 36 developed rheumatic heart disease with significant left-sided heart involvement. No significant demographic difference was present between rheumatic heart disease patients and controls (p > 0.05). miR-101 and miR-1183 expressions significantly reduced by 4.5-fold in acute rheumatic fever patients compared to controls (p : 0.029 and p : 0.024, respectively). Family history was found to be significantly associated with 9-fold reduced miR-1183 expression in acute rheumatic fever patients (p : 0.005). The expression of miR-1183 in acute rheumatic fever children with carditis in general and severe carditis was significantly reduced 4.5- and 9-fold, respectively (p : 0.024 and p : 0.007, respectively). In acute rheumatic fever cases with moderate-severe carditis and patients who did not develop rheumatic heart disease, miR-1183 expression significantly reduced 8.3-fold and 9-fold, respectively (p : 0.015 and p : 0.019, respectively). The ROC analysis revealed that miR-101 and miR-1183 were statistically significant for acute rheumatic fever diagnosis (AUC: 0.64 for both miRNAs).

Conclusions:

Significantly lower plasma expressions of miR-101 and miR-1183 in acute rheumatic fever patients, especially in cases with moderate-severe carditis, might indicate the potential use of these miRNAs as diagnostic biomarkers.

Keywords

Acute rheumatic feverrheumatic heart diseasemiRNAcarditis
Type
Original Article
Information
Cardiology in the Young , First View , pp. 1 - 8
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arvind, B, Ramakrishnan, S. Rheumatic fever and rheumatic heart disease in children. Indian J Pediatr 2020; 87: 305–311. DOI: 10.1007/s12098-019-03128-7.CrossRefGoogle ScholarPubMed
Watkins, DA, Johnson, CO, Colquhoun, SM et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med 2017; 377: 713–722. DOI: 10.1056/NEJMoa1603693.CrossRefGoogle ScholarPubMed
Gewitz, MH, Baltimore, RS, Tani, LY et al. Revision of the Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography. Circulation 2015; 131: 1806–1818. DOI: 10.1161/CIR.0000000000000205.CrossRefGoogle Scholar
Reményi, B, Wilson, N, Steer, A et al. World heart federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guideline. Nat Rev Cardiol 2012; 9: 297–309. DOI: 10.1038/nrcardio.2012.7.CrossRefGoogle ScholarPubMed
Bright, PD, Mayosi, BM, Martin, WJ. An immunological perspective on rheumatic heart disease pathogenesis: more questions than answers. Heart 2016; 102 1527–1532. DOI: 10.1136/heartjnl-2015-309188.CrossRefGoogle ScholarPubMed
Yousry, SM, Sedky, Y, Sobieh, A. Association of IL-4 (intron 3) and IL-10 (−1082) gene polymorphisms with risk of mitral valve disease in children with rheumatic heart disease. Cardiol Young 2016; 26: 1290–1296. DOI: 10.1017/S1047951115002413.CrossRefGoogle Scholar
Catarino, SJ, Andrade, FA, Boldt, ABW et al. Sickening or healing the heart? The association of ficolin-1 and rheumatic fever. Front Immunol 2018; 9: 3009. DOI: 10.3389/fimmu.2018.03009.CrossRefGoogle ScholarPubMed
Zheng, D, Chen, X, Li, N et al. Differentially methylated regions in patients with rheumatic heart disease and secondary pulmonary arterial hypertension. Exp Ther Med 2017; 14: 1367–1372. DOI: 10.3892/etm.2017.4652.CrossRefGoogle ScholarPubMed
Asulin, N, Volinsky, N, Grosman-Rimon, L et al. Differential microRNAs expression in calcified versus rheumatic aortic valve disease. J Card Surg 2020; 35: 1508–1513. DOI: 10.1111/jocs.14636.CrossRefGoogle ScholarPubMed
Çakmak, HA, Demir, M. MicroRNA and cardiovascular diseases. Balkan Med J 2020; 37: 60–71. DOI: 10.4274/balkanmedj.galenos.2020.2020.1.94.Google ScholarPubMed
Song, Y, Higgins, H, Guo, J et al. Clinical significance of circulating microRNAs as markers in detecting and predicting congenital heart defects in children. J Transl Med 2018; 16: 42. DOI: 10.1186/s12967-018-1411-0.CrossRefGoogle ScholarPubMed
Siddeek, B, Mauduit, C, Yzydorczyk, C et al. At the heart of programming: the role of micro-RNAs. J Dev Orig Health Dis 2018; 9: 615–631. DOI: 10.1017/S2040174418000387.CrossRefGoogle ScholarPubMed
Wang, W, Zhang, Y, Zhu, B et al. Plasma microRNA expression profiles in Chinese patients with rheumatoid arthritis. Oncotarget 2015; 6: 42557–42568. DOI: 10.18632/oncotarget.6449.CrossRefGoogle ScholarPubMed
Chen, A, Wen, J, Lu, C et al. Inhibition of miR-155-5p attenuates the valvular damage induced by rheumatic heart disease. Int J Mol Med 2020; 45: 429–440. DOI: 10.3892/ijmm.2019.4420.Google ScholarPubMed
Lu, Q, Sun, Y, Duan, Y et al. Comprehensive microRNA profiling reveals potential augmentation of the IL1 pathway in rheumatic heart valve disease. BMC Cardiovasc Disord 2018; 18: 53. DOI: 10.1186/s12872-018-0788-2.CrossRefGoogle ScholarPubMed
Gumus, G, Giray, D, Bobusoglu, O et al. MicroRNA values in children with rheumatic carditis: a preliminary study. Rheumatol Int 2018; 38: 1199–1205. DOI: 10.1007/s00296-018-4069-2.CrossRefGoogle ScholarPubMed
Dong, H, Sun, Y, Shan, F et al. Down-regulation of miR-101 contributes to rheumatic heart disease through up-regulating TLR2. Med Sci Monit 2015; 21: 1500–1506. https://dx.doi.org/10.12659/MSM.893540.Google ScholarPubMed
Li, N, Lian, J, Zhao, S et al. Detection of differentially expressed MicroRNAs in rheumatic heart disease: miR-1183 and miR-1299 as potential diagnostic biomarkers. Biomed Res Int 2015; 2015: 1–11. DOI: 10.1155/2015/524519 Google ScholarPubMed
Heart Foundation New Zealand. Algorithm 3: guide for the duration of secondary prophylaxis in acute rheumatic fever (ARF) 2020. https://assets.heartfoundation.org.nz/documents/shop/heart-healthcare/non-stock-resources/secondary-prophylaxis-rheumatic-fever-algorithm.pdf.Google Scholar
Zhao, X, Wang, K, Liao, Y et al. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFβRI on cardiac fibroblasts. Cell Physiol Biochem 2015; 35: 213–226. DOI: 10.1159/000369689.CrossRefGoogle ScholarPubMed
Balashanmugam, MV, Shivanandappa, TB, Nagarethinam, S et al. Analysis of differentially expressed genes in coronary artery disease by integrated microarray analysis. Biomolecules 2020; 10: 35. DOI: 10.3390/biom10010035.CrossRefGoogle Scholar
Pokhrel, S, Guotian, Y. MicroRNA and its role in cardiovascular disease. World J Cardiovasc Dis 2017; 7: 340–357. DOI: 10.4236/wjcd.2017.710032.CrossRefGoogle Scholar
Oury, C, Servais, L, Bouznad, N et al. MicroRNAs in valvular heart diseases: potential role as markers and actors of valvular and cardiac remodeling. Int J Mol Sci 2016; 17: 1120. DOI: 10.3390/ijms17071120.CrossRefGoogle ScholarPubMed
Dai, L, Zhang, X, Hu, X et al. Silencing of microRNA-101 prevents IL-1β-induced extracellular matrix degradation in chondrocytes. Arthritis Res Ther 2012; 14: R268. DOI: 10.1186/ar4114.CrossRefGoogle ScholarPubMed
Chen, C, Ponnusamy, M, Liu, C et al. MicroRNA as a therapeutic target in cardiac remodeling. Biomed Res Int 2017; 2017: 1–25. DOI: 10.1155/2017/1278436.Google ScholarPubMed
Sayed, D, Abdellatif, M. MicroRNAs in development and disease. Physiol Rev 2011; 91: 827–887. DOI: 10.1152/physrev.00006.2010.CrossRefGoogle ScholarPubMed
Wang, G, Rao, N, Liu, D et al. Analysis of potential roles of combinatorial microRNA regulation in occurrence of valvular heart disease with atrial fibrillation based on computational evidences. PLoS One 2019; 14: e0221900. DOI: 10.1371/journal.pone.0221900.CrossRefGoogle ScholarPubMed
Wu, Y, Fan, Z, Chen, Z et al. Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a. Mol Cell Biochem 2020; 470: 41–51. DOI: 10.1007/s11010-020-03743-5.CrossRefGoogle ScholarPubMed
Ding, H, Xu, Y, Jiang, N. Upregulation of miR-101a suppresses chronic renal fibrosis by regulating KDM3A via blockade of the YAP-TGF-β-smad signaling pathway. Mol Ther - Nucleic Acids 2020; 19: 1276–1289. DOI: 10.1016/j.omtn.2020.01.002.CrossRefGoogle ScholarPubMed
Rainer, J, Meraviglia, V, Blankenburg, H et al. The arrhythmogenic cardiomyopathy-specific coding and non-coding transcriptome in human cardiac stromal cells. BMC Genomics 2018; 19: 491. DOI: 10.1186/s12864-018-4876-6.CrossRefGoogle ScholarPubMed
Yan, Y, Shi, R, Yu, X et al. Identification of atrial fibrillation-associated microRNAs in left and right atria of rheumatic mitral valve disease patients. Genes Genet Syst 2019; 94: 23–34. DOI: 10.1266/ggs.17-00043.CrossRefGoogle ScholarPubMed
Cao, S, Li, L, Li, J, Zhao, H. MiR-1299 impedes the progression of Non-small-cell lung cancer through EGFR/PI3K/AKT signaling pathway. Onco Targets Ther 2020; 13: 7493–7502. DOI: 10.2147/OTT.S250396.CrossRefGoogle ScholarPubMed
Li, W, Fang, Q, Zhong, P et al. EGFR inhibition blocks palmitic acid-induced inflammation in cardiomyocytes and prevents hyperlipidemia-induced cardiac injury in mice. Sci Rep 2016; 6: 24580. DOI: 10.1038/srep24580.CrossRefGoogle ScholarPubMed
Barrick, CJ, Roberts, RB, Rojas, M et al. Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Circ Physiol 2009; 297: H65–H75. DOI: 10.1152/ajpheart.00866.2008.CrossRefGoogle Scholar
Felekkis, K, Papaneophytou, C. Challenges in using circulating Micro-RNAs as biomarkers for cardiovascular diseases. Int J Mol Sci 2020; 21: 561. DOI: 10.3390/ijms21020561.CrossRefGoogle ScholarPubMed